00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
21:37 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

PyL: Ph II/III OSPREY started

Progenics began the open-label, North American Phase II/III OSPREY trial to evaluate a single dose of IV PyL in about 300 patients with high-risk prostate cancer with recurrence or metastatic disease. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX),...